Publications by authors named "Mara Bonelli"

Claim this Profile
C
Correction: The anti-tumor efficacy of CDK4/6 Inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells.
Daniele Cretella, Andrea Ravelli, Claudia Fumarola, Silvia La Monica, Graziana Digiacomo, Mara Bonelli

J Exp Clin Cancer Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Cavazzoni et al. Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer. 2020, , 666.
Andrea Cavazzoni, Graziana Digiacomo, Roberta Alfieri, Silvia La Monica, Claudia Fumarola, Mara Bonelli

Cancers (Basel)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myrtleciclib, a CDK4/6/9 Inhibitor for the Treatment of Aggressive Cancers.
Davide De Forni, Barbara Poddesu, Giulia Cugia, Mara Bonelli, Maricla Galetti

Curr Med Chem· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Mesenchymal stromal cells loaded with Paclitaxel (PacliMES) a potential new therapeutic approach on mesothelioma" [Biochem. Pharmacol. 214 (2023) 115678].
Valentina Coccè, Mara Bonelli, Silvia La Monica, Roberta Alfieri, Luisa Doneda

Biochem Pharmacol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells.
Graziana Digiacomo, Claudia Fumarola, Silvia La Monica, Mara Bonelli, Andrea Cavazzoni

Front Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines.
Kamal Eltayeb, Roberta Alfieri, Claudia Fumarola, Mara Bonelli, Maricla Galetti

Biochem Pharmacol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments.
Claudia Fumarola, Silvia La Monica, Mara Bonelli, Silvia Zoppi, Roberta Alfieri

Biochem Pharmacol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models.
Silvia La Monica, Federica Vacondio, Kamal Eltayeb, Alessio Lodola, Francesco Volta, Mara Bonelli

Sci Rep· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators.
Francesco Volta, Silvia La Monica, Alessandro Leonetti, Letizia Gnetti, Mara Bonelli

Target Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mesenchymal stromal cells loaded with Paclitaxel (PacliMES) a potential new therapeutic approach on mesothelioma.
Valentina Coccè, Mara Bonelli, Silvia La Monica, Roberta Alfieri, Luisa Doneda

Biochem Pharmacol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Micro-fragmented Fat Inhibits the Progression of Human Mesothelioma Xenografts in Mice.
Silvia La Monica, Valentina Coccé, Mara Bonelli, Giulio Alessandri, Roberta Alfieri

Curr Cancer Drug Targets· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells.
Rita Terenziani, Maricla Galetti, Silvia La Monica, Claudia Fumarola, Silvia Zoppi, Mara Bonelli

Cancers (Basel)· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells.
Graziana Digiacomo, Claudia Fumarola, Silvia La Monica, Mara Bonelli, Andrea Cavazzoni

Front Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapeutic Approaches in Malignant Pleural Mesothelioma.
Rita Terenziani, Silvia Zoppi, Claudia Fumarola, Roberta Alfieri, Mara Bonelli

Cancers (Basel)· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of Human Malignant Pleural Mesothelioma Growth by Mesenchymal Stromal Cells.
Valentina Coccè, Silvia La Monica, Mara Bonelli, Giulio Alessandri, Roberta Alfieri

Cells· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib.
Silvia La Monica, Claudia Fumarola, Daniele Cretella, Mara Bonelli, Roberta Minari

Cancers (Basel)· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines.
Graziana Digiacomo, Claudia Fumarola, Silvia La Monica, Mara A Bonelli, Daniele Cretella

Front Oncol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells.
Mara Bonelli, Rita Terenziani, Silvia Zoppi, Claudia Fumarola, Silvia La Monica

Int J Mol Sci· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer.
Andrea Cavazzoni, Graziana Digiacomo, Roberta Alfieri, Silvia La Monica, Claudia Fumarola, Mara Bonelli

Cancers (Basel)· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation.
Mara Bonelli, Silvia La Monica, Claudia Fumarola, Roberta Alfieri

Biochem Pharmacol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion.
Silvia La Monica, Roberta Minari, Daniele Cretella, Mara Bonelli, Claudia Fumarola

Target Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells.
Daniele Cretella, Claudia Fumarola, Mara Bonelli, Roberta Alfieri, Silvia La Monica

Sci Rep· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC.
Silvia La Monica, Roberta Minari, Daniele Cretella, Lisa Flammini, Claudia Fumarola, Mara Bonelli

J Exp Clin Cancer Res· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines.
Claudia Fumarola, Nicole Bozza, Riccardo Castelli, Francesca Ferlenghi, Giuseppe Marseglia, Mara Bonelli

Front Oncol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR.
Riccardo Castelli, Nicole Bozza, Andrea Cavazzoni, Mara Bonelli, Federica Vacondio

Eur J Med Chem· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis